Australian guinea pigs step up for virus trial

Original article by Natasha Robinson
The Australian Financial Review – Page: 1 & 5 : 20-May-20

Australia-based Q-Pharm will shortly commence a phase one clinical trial of a coronavirus vaccine that is being developed by US biopharmaceutical group Novavax. Some 131 people in Melbourne and Brisbane have volunteered to participate in the clinical trial. Q-Pharm will also undertake phase 1 clinical trials of a potential vaccine that being developed by the University of Queensland. Meanwhile, the Walter & Eliza Hall Institute of Medical Research will commence a clinical trial of antimalarial drug hydroxychloroquine.

CORPORATES
Q-PHARM PTY LTD, UNIVERSITY OF QUEENSLAND, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Research Australia and Roy Morgan partner to reveal Australians’ views on health and medical research (HMR) in a changing landscape of healthcare

Original article by Roy Morgan
Market Research Update – Page: Online : 17-Sep-18

Research Australia and Roy Morgan have released the results of the 2018 Health & Medical Research Public Opinion Poll. Celebrating the 15th year of the annual poll, Research Australia and Roy Morgan have hosted an official launch in The Cellar of Tonic House, Roy Morgan’s unique office function room. Roy Morgan CEO Michele Levine enlightened attendees on trust and distrust in the healthcare space, and how a much more discerning public, along with the advent of technology are pushing back against what they perceive as unfair practice. Research Australia CEO Nadia Levin shared some of the key outcomes from the poll to an audience from across the health and medical research pipeline, including representation from Ausbiotech, GSK, AAMRI, the University of Melbourne, HealthConsult, the Department of Health & Human Services, ARCS and The Walter & Eliza Hall institute of Medical Research.

CORPORATES
ROY MORGAN LIMITED, RESEARCH AUSTRALIA LIMITED

Business in fight against dementia

Original article by Sarah Thompson, James Chessell
The Australian Financial Review – Page: 3 : 24-Mar-15

The Centre for Healthy Brain Ageing’s Dementia Momentum program, to be launched on 24 March 2015, will use "big data" to seek better understanding of dementia. The program is supported by prominent businessmen including McGrathNicol founder Tony McGrath, Anchorage Capital Partners founder Phil Cave, CHAMP Private Equity founder Bill Ferris, and Genworth Mortgage Insurance chairman Richard Grellman. The latter’s wife Suellen suffers from early-onset dementia

CORPORATES
UNIVERSITY OF NEW SOUTH WALES. CENTRE FOR HEALTHY BRAIN AGEING, McGRATH NICOL AND PARTNERS SERVICES PTY LTD, ANCHORAGE CAPITAL PARTNERS PTY LTD, CHAMP PRIVATE EQUITY PTY LTD, GENWORTH MORTGAGE INSURANCE AUSTRALIA LIMITED – ASX GMA, THE GARVAN INSTITUTE OF MEDICAL RESEARCH, KPMG AUSTRALIA PTY LTD, WORLD DEMENTIA COUNCIL, DELOITTE ACCESS ECONOMICS PTY LTD

Breakthrough by Australian team sheds light on cancer genes

Original article by Nicky Phillips
The Sydney Morning Herald – Page: 2 : 3-Feb-15

Scientists at Australia’s Garvan Institute of Medical Research, led by Susan Clark, have achieved a first in the fight against cancer. The team have translated the breast cancer methylome, in what is seen as the next step after the decoding of the human genome. Methyl groups are attached to sections of DNA, and influence how genes are expressed in different cell types. Experts say the seminal work by Clark and her colleagues will bring major advances in cancer medicine

CORPORATES
THE GARVAN INSTITUTE OF MEDICAL RESEARCH, ICON CANCER CARE, NATIONAL BREAST CANCER FOUNDATION

Perth toddler first person to get artificial pancreas

Original article by Aleisha Orr
The Age – Page: 10 : 22-Jan-15

A team at Princess Margaret Hospital for Children in Perth has fitted a newly developed medical device that functions as an artificial pancreas to a four-year-old boy suffering from type-1 diabetes. The battery-powered pump supplies insulin in doses according to automated readings of glucose levels, in order to prevent hypoglycaemic attacks. The product is already freely available to diabetes patients, including adults, but the cost is still high at $A10,000

CORPORATES
PRINCESS MARGARET HOSPITAL

Aspirin study raises hopes for dementia prevention

Original article by Kathy Evans
The Age – Page: 11 : 5-Jan-15

The US National Institutes of Health agency is funding new research by Monash University’s School of Public Health & Preventive Medicine in Melbourne. The aim is to establish whether aspirin’s anti-inflammatory properties can be used to prevent deafness, blindness and dementia in older patients. The "ASPirin in Reducing Events in the Elderly" (ASPREE) project also involves the Berman Centre for Outcomes & Clinical Research in Minneapolis, and will have 19,000-plus test subjects

CORPORATES
MONASH UNIVERSITY, UNITED STATES. DEPT OF HEALTH AND HUMAN SERVICES. NATIONAL INSTITUTES OF HEALTH, MINNEAPOLIS MEDICAL RESEARCH FOUNDATION. BERMAN CENTER FOR OUTCOMES AND CLINICAL RESEARCH

Dementia a personal issue for campaigner

Original article by Rachel Browne
The Sydney Morning Herald – Page: 11 : 9-Dec-14

Richard Grellman is one of about 30 prominent Australian businesspeople supporting the Dementia Momentum corporate philanthropic endowment. The wife of the AMP Life Insurance, Genworth Mortgage Insurance and Crowe Horwath chair developed young onset Alzheimer’s disease. Another backer of the entity, established to provide funding for research into the affliction, is Anchorage Capital Partners MD Phillip Cave

CORPORATES
DEMENTIA MOMENTUM, AMP LIFE LIMITED, AMP LIMITED – ASX AMP, GENWORTH MORTGAGE INSURANCE AUSTRALIA LIMITED – ASX GMA, CROWE HORWATH AUSTRALASIA LIMITED – ASX CRH, ANCHORAGE CAPITAL PARTNERS PTY LTD, UNIVERSITY OF NEW SOUTH WALES. CENTRE FOR HEALTHY BRAIN AGEING, AUSTRALIA. NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL

Obese youth can lose eight years off their lives

Original article by Nicky Phillips
The Sydney Morning Herald – Page: 9 : 8-Dec-14

Margaret Allman-Farinelli, nutrition researcher at the University of Sydney, says new studies show that weight control programs aimed at young adults only have an effect in about half of all cases. Australians between the ages of 25 and 34 on average put on 6.7 kilograms over that period, as their activity levels drop and they start cooking their own meals. Meanwhile, new modelling conducted in Canada suggests that those overweight with a Body Mass Index (BMI) of 25 to 30 face a reduction in life expectancy of three years, and those obese with a BMI between 30 and 35 one of up to eight years

CORPORATES
UNIVERSITY OF SYDNEY. CHARLES PERKINS CENTRE

Bionic eye closer to trials on humans

Original article by Bridie Smith
The Age – Page: 8 : 3-Dec-14

Monash University is matching dollar-for-dollar the donations by the charitable foundations of chancellor Alan Finkel and entrepreneur Marc Besen to the Monash Vision Group. The funding of $A3m in total will enable the bionic eye researchers to proceed to human trials in 2015. The expenditure on the project has averaged $A2.5m per annum, but Monash Vision director Arthur Lowery notes that there will be no further grants by the Australian Research Council. Monash Vision is a joint effort of Monash University, Alfred Health, MiniFAB and Grey Innovation

CORPORATES
MONASH VISION PTY LTD, MONASH UNIVERSITY, ALFRED HEALTHCARE GROUP, MINIFAB (AUST) PTY LTD, GREY INNOVATION PTY LTD, BIONIC VISION AUSTRALIA, AUSTRALIAN RESEARCH COUNCIL, AUSTRALIA. NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL, BESEN FAMILY FOUNDATION

Future fund at risk without $7 GP fee

Original article by Joanna Heath
The Australian Financial Review – Page: 6 : 27-Nov-14

The Australian Government’s decision to no longer pursue the $A7 co-payment for visits to general practitioners in the hostile Senate may also jeopardise the proposed Medical Research Future Fund. Its funding had been tied to the revenue to come from the abandoned measure, and the Department of Finance says it has no other source. Health Minister Peter Dutton previously said the fund would still be created, but with reduced resources. A Medical Research Future Fund Action Group lobbying body contains the CEOs of UBS, Wesfarmers and ASX

CORPORATES
AUSTRALIA. DEPT OF FINANCE, AUSTRALIA. DEPT OF HEALTH, ASX LIMITED – ASX ASX, WESFARMERS LIMITED – ASX WES, UBS HOLDINGS PTY LTD